Valuation: Actinium Pharmaceuticals, Inc.

Market Cap 3.18Cr 2.73Cr 2.56Cr 2.34Cr 4.41Cr 302.88Cr 4.43Cr 30Cr 12Cr 152.8Cr 12Cr 12Cr 506.1Cr P/E 2026 *
7.21x
P/E 2027 * -1.49x
Enterprise Value 3.18Cr 2.73Cr 2.56Cr 2.34Cr 4.41Cr 302.88Cr 4.43Cr 30Cr 12Cr 152.8Cr 12Cr 12Cr 506.1Cr EV / Sales 2026 *
2.72x
EV / Sales 2027 * -
Free-Float
97.66%
Yield 2026 *
-
Yield 2027 * -
15/08 Actinium Pharmaceuticals Expands Manufacturing Capacity for Actimab-A Program CI
15/08 Actinium Pharmaceuticals, Inc. Amends Its Investigational New Drug CI
08/08 Actinium Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 CI
03/06 Actinium Pharmaceuticals Presents New Data on Atnm-400 Demonstrating Potent Activity in Prostate Cancer Models Resistant to All Three Approved Androgen Receptor Inhibitors CI
01/06 Actinium Pharmaceuticals, Inc. Appoints Steffen Heeger as Chief Medical Officer CI
01/06 Actinium Pharmaceuticals Presents New Radiochemistry Data Demonstrating That CAR Optimization Improves Tumor Targeting and Pharmacokinetics of Actinium-225 Radioconjugates CI
30/05 Actinium Pharmaceuticals - receives two Canadian patent allowances for Actimab-A and Iomab-Act programs RE
30/05 Actinium Pharmaceuticals Receives Patent Allowances for Actimab-A and Iomab-Act Programs in Canada CI
09/05 Actinium Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
06/05 Actinium Pharmaceuticals Announces Three SNMMI 2026 Presentations Highlighting Differentiated Profile of Atnm-400 Across Lung and Prostate Cancer and Radioconjugate Optimization CI
22/04 Actinium Pharmaceuticals, Inc. Highlights Transcriptional Reprogramming As Key Mechanism Underpinning Mutation-Agnostic Activity Of Actimab-A In AML CI
22/04 Actinium Pharmaceuticals, Inc. Announces Compelling Pan-Tumor Data for ATNM-400 Demonstrating Broad Efficacy Across Prostate, Lung, and Breast Cancer Models At the 2026 American Association of Cancer Research Annual Meeting CI
07/04 Actinium Pharmaceuticals Announces New Pan-Tumor Preclinical Data for Atnm-400 in Solid Tumors and Differentiated Mechanism for Actimab-A in Aml CI
1 day-6.48%
1 week-10.62%
Current month+20.68%
1 month+17.44%
3 months-12.93%
6 months-12.17%
Current year-25.74%
1 week 1.01
Extreme 1.01
1.14
1 month 0.74
Extreme 0.735101
1.15
Current year 0.74
Extreme 0.735101
1.53
1 year 0.74
Extreme 0.735101
1.8
3 years 0.74
Extreme 0.735101
10.24
5 years 0.74
Extreme 0.735101
15.12
10 years 0.74
Extreme 0.735101
64.5
Manager TitleAgeSince
Chief Executive Officer 62 09/06/2017
Chief Tech/Sci/R&D Officer - 01/06/2026
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 71 01/01/2008
Chairman 62 01/10/2013
Director/Board Member 68 08/11/2013
Date Insider Type Main position Quantity % Market Cap.
18/08/25 Tax

Chief Executive Officer

1,20,900 0.3876%
31/03/25 Issuer sale

Chief Financial Officer

7,06,588 2.2650%
31/03/25 Issuer sale

Chief Executive Officer

23,85,976 7.6484%
Change 5-day change 1-year change 3-year change Capi.($)
-6.48%-10.62%-43.26%-83.22% 3.18Cr
+3.31%-3.70%+61.03%+103.64% 7.04TCr
+0.27%+1.78%+48.29%+91.87% 6.54TCr
-1.31%-0.50%+7.41%-4.29% 2.83TCr
-0.20%+2.03%+59.48%+11.93% 2.66TCr
+0.40%-4.80%-5.89%+469.55% 2.72TCr
-0.23%+0.33%+36.86%-16.09% 2.01TCr
+1.02%+6.43%+269.42%+420.34% 2.06TCr
+2.69%+0.28%+15.34%+555.83% 1.59TCr
-1.09%+3.14%+46.32%+155.12% 1.39TCr
Average -0.13%+1.04%+49.50%+170.47% 2.88TCr
Weighted average by Cap. +0.95%+0.72%+56.41%+158.06%

Financials

2026 *2027 *
Net sales 1.17Cr 1Cr 93.99L 85.84L 1.62Cr 111.27Cr 1.63Cr 11Cr 4.31Cr 56Cr 4.38Cr 4.29Cr 185.93Cr -
Net income 49.06L 42.11L 39.53L 36.1L 68.13L 47Cr 68.46L 4.68Cr 1.81Cr 24Cr 1.84Cr 1.8Cr 78Cr -3.17Cr -2.72Cr -2.55Cr -2.33Cr -4.4Cr -302.41Cr -4.42Cr -30Cr -12Cr -152.56Cr -12Cr -12Cr -505.31Cr
Net Debt - -
Logo Actinium Pharmaceuticals, Inc.
Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company pioneering the development of targeted radiotherapies to address significant unmet medical needs in oncology. It operates a pipeline of both early and later stage development programs with two novel solid tumor product candidates, ATNM-400 and Actimab-A, with pan-tumor potential; Actimab-A, which is also being developed as a therapeutic backbone for acute myeloid leukemia and myelodysplastic syndrome in partnership with the National Cancer Institute (NCI), and two targeted conditioning agents, Iomab-B for bone marrow transplant and Iomab-ACT for cell & gene therapies. Its solid tumor asset, ATNM-400, targets a novel antigen distinct from PSMA, with demonstrated preclinical activity across metastatic castration-resistant prostate cancer (mCRPC), non-small cell lung cancer (NSCLC), and breast cancer. Its hematology franchise includes Actimab-A, Iomab-B and Iomab-ACT, which are CD45-targeting conditioning agents.
Employees
27
Date Price Change Volume
26/26/26 $1.010 -6.48% 1,45,244
25/26/25 $1.080 +2.86% 1,59,003
24/26/24 $1.050 -4.55% 64,454
21/26/21 $1.100 -1.79% 1,44,008
20/26/20 $1.120 -0.88% 1,21,416
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
1.010USD
Average target price
3.500USD
Spread / Average Target
+246.53%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ATNM Stock